Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Hepion Pharmaceuticals Q3 2026 Results: Net Loss of $4.58M, Loss Widens

Hepion Pharmaceuticals reported a net loss of $6.6 million for the nine months ended September 30, 2026, compared to a $7.6 million loss in the prior year period. The company's financial position shows a stockholders' deficit of $4.0 million, and management highlighted significant uncertainties regarding their ability to raise additional capital to continue as a going concern.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.6-0.5
EPS (diluted, $ a share)$-0.06$-0.04

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: HEPA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Hepion Pharmaceuticals, Inc.: key numbers

Share price
$0.0903Close, Nov 16
Market cap
$11.3M
Shares outstanding
125.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Hepion Pharmaceuticals, Inc.

All →
4:31 PM ET 8-K
M&A Deal

Hepion Pharmaceuticals Signs $4.38M M&A Deal with Gravitas Life Sciences, LLC

Hepion Pharmaceuticals completed the acquisition of all issued and outstanding membership interests of Gravitas Life Sciences, LLC from Gravitas Collective Corp. The total consideration consisted of $2.0 million in cash, 25,000,000 shares of common stock valued at $2.25 million, and an additional $135,000 payment. The transaction is classified as a related party transaction as several Hepion directors are also officers of Gravitas Life Sciences.

Value
$4.38M
Counterparty
Gravitas Life Sciences, LLC
4:31 PM ET Form 4
Insider Buying

Hepion Pharmaceuticals Insider Danina Fisher Buys $10K of Stock

Danina Fisher bought 200,000 shares of Hepion Pharmaceuticals, Inc. at $0.05 a share, worth $10K in total on Sep 29, 2026. Shares held after the trade: 200,000.

Value
$10K
Shares
200,000
Price
$0.0500
Trade date
Sep 29, 2026
9:25 AM ET 8-K
Other 8-K Filing

Hepion Pharmaceuticals Other 8-K Filing

Hepion Pharmaceuticals filed a Certificate of Amendment to its Certificate of Incorporation to increase the authorized number of shares of common stock to 750,000,000. The amendment became effective upon filing on October 1, 2026. This action increases the company's capacity for future share issuances but does not represent an active capital raise in this filing.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.